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1. Introduction 
Over the last decade, there has been a significant increase in the number of clinical trials 
taking place in sub-Saharan Africa in a concerted effort to identify safe and effective 
prevention and treatment strategies to combat the heavy burden of infectious diseases in 
this region [1-3]. This is because numerous viral, parasitic and bacterial diseases are endemic 
in this region, including: 66% of the global HIV/AIDS infections, 31% of tuberculosis 
infections, and 86% of malaria cases [3, 4]. Routine capacity for clinical laboratory testing is 
also increasing in Africa. Clinical trials and clinical care in sub-Saharan Africa require 
accurate laboratory reference intervals for appropriate assessment of patients/participants, 
monitoring disease progression, and reporting of possible toxicity and adverse events.  
This is particularly important in phase I and II clinical trials. Phase I trials often enroll a 
small group of healthy participants in order to determine the metabolic and pharmacologic 
actions of drugs, side effects associated with increasing doses and early evidence of efficacy. 
Phase II trials on the other hand are controlled clinical studies conducted to evaluate efficacy 
of drug/vaccine for a particular indication in a larger group of participants and to further 
evaluate its safety. Many HIV vaccine trials are slated for Phase I–III trials in Africa. The 
inception of the US President's Emergency Plan for AIDS Relief in 2004, with a mandate to 
treat 2 million HIV infections with anti-retroviral therapy by 2008 has accelerated the 
implementation of lymphocyte immunophenotyping in urban and rural areas in Africa as 
initiation of therapy is often predicated on absolute CD4 T- lymphocyte counts. Central to 
any HIV vaccine and/or care and treatment program is the capability to measure absolute 
CD4 counts. CD4 counts are important in the context of breakthrough infections during HIV 
vaccine trials and informing treatment. Correct diagnosis in patient management often 
involves accurate interpretation of results from laboratory testing [5]. Hence it is critical for 
medical professionals to have access to an accurate management resource such as reference 
intervals. 
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Historically, clinical studies as well as routine clinical patient management in most African 
countries have relied on European-generated automated instrument values, US established 
reference intervals or the U.S. NIH division of AIDS (DAIDS) toxicity grading tables in 
assessing clinical parameters in study participants. The US-established reference intervals 
are obtained from the Massachusetts General Hospital reference values and serve as the 
standard reference interval comparison for most studies [6]. The DAIDS toxicity tables, also 
derived from a Caucasian population, are used for grading the severity of adult and 
pediatric adverse events, whether or not they are considered to be related to the study 
intervention [7]. DAIDS provides guidelines for estimating severity of adverse events using  
specific reference intervals (Table 1) as criteria for determining what is ‘normal’ and among 
abnormal values, how to grade the severity of the abnormality. 
 
PARAMETER GRADE 1 
MILD 
GRADE 2 
MODERATE 
GRADE 3 
SEVERE 
GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
HEMOGLOBIN  10.0 – 10.9  g/dL 9.0 – 9.9  g/dL 7.0 – 8.9  g/dL < 7.0  g/dL 
NEUTROPHILS 
1.0 – 
1.3 x 109 cells/L 
0.75 –  
0.999 x 109cells/L 
0.5 –  
0.749 x 109cells/L < 0.5 x 109cells/L 
Adult and pediatric values for age >57 days, HIV-negative from the DAIDS toxicity tables version 1.0, December 2004; 
clarification August 2009. 
Table 1. Examples of DAIDS criteria of estimating severity grading based on laboratory parameters. 
Reference values, in general, refer to the value or test result obtained by the observation or 
measurement of a particular type of quantity on an adequate number of persons (reference 
sample group) selected to represent the general population. Reference values are usually 
presented as reference intervals which refer to the interval between, and including two 
reference limits i.e., from the lower reference limit to the upper reference limit defined by a 
specific percentage (usually 95%). In certain parameters such as absolute counts of 
monocytes, eosinophils and basophils, only one reference limit (decision limit), more often 
the upper reference limit is of biological significance hence the lower reference limit 
assumes a value of zero.  
Reference values go hand in hand with toxicity grading or decision limits, which can be 
defined as specific levels of the analyte that correspond to mild to life threatening clinical 
situations. Toxicity grading is particularly useful in the decision-making process of 
interpreting a measured value and assessing the health status of the subject being tested. For 
this reason reference values or toxicity grading are routinely used in clinical trials at 
enrollment to determine eligibility, establish baseline measures, and also during the course 
of the trial to monitor the participants’ health. Moreover, several analytes are used either as 
markers for the possible presence of a disease or as direct evidence for that disease. 
Reference values, especially hematological and immunologic indices, are influenced by such 
factors as genetics, dietary patterns, pregnancy, gender, age, ethnic origin and prior 
exposure to environmental pathogens. Thus, it is important to consider these factors when 
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applying reference intervals in diagnostics as well as in recruitment in clinical trials. 
According to the Clinical Laboratory and Standards Institute (CLSI) guidelines [8], it is 
recommended that laboratories establish their own reference intervals from the local 
population or validate the use of those obtained from a different setting. Despite this, 
clinicians and researchers in Africa have continued to use reference values of European or 
North American populations. Our group in Kenya has recently published reference 
intervals based on the CLSI guidelines and are currently assisting regional laboratories to 
establish their own reference intervals[9]. 
In this chapter, we give a brief background on the current status of participant recruitment 
in clinical trials and patient management in Africa. We will also describe how to select a 
reference population from which to derive the reference sample group. In addition, we 
describe various studies advocating the establishment of reference intervals performed in 
different regions of the African continent including our own. These studies show differences 
in hematological, biochemical and immunologic parameters between various African 
populations but these differences are statistically insignificant. However, most 
hematological, biochemical and immunologic parameters considered in the African studies 
are significantly different when compared to American and European derived values. This 
chapter will also discuss the proposed partitioning of adolescent males from adults given 
their increased recruitment into clinical trials. Adult males have significantly higher values 
for most hematological and biochemical parameters and we provide an explanation why 
this is so. While pregnant women and infants undergo physiological processes that alter 
their hematological and biochemical parameters, the partitioning of these cohorts has been 
slow. We discuss how pregnancy induces these changes and describe the particular 
parameters affected. We also highlight the dynamic changes in these parameters during 
infancy and how they differ from western-derived values. In this chapter, we also illustrate 
the downside of using inappropriate reference intervals in the recruitment of participants in 
clinical trials and patient management. We show how the use of such values results in 
exclusion of clinically healthy participants from clinical trials and may lead to inappropriate 
reporting of adverse events during the course of these studies.  This potentially results in 
escalation of costs in the conduct of clinical trials. In this book chapter, we also propose the 
development of laboratory-derived African toxicity grades that, in addition to the already 
developed reference values, would be used for reporting adverse events in clinical trials and 
for determining critical values in routine health care.   
2. Use of reference intervals, consequence of misclassification and 
selection of a reference population 
2.1. The use of reference intervals 
Reference intervals are useful both in the clinical and research environment. Medical 
laboratory reference intervals are primarily used for clinical purposes. They can be used as 
an indicator of good health. Alternatively, reference intervals/limits can be used to screen for 
physiological or pathological conditions hence important in routine health assessment, 
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particularly for screening of anemia, blood disorders and diseases of the immune system. 
Reference intervals are important for accurate interpretation of laboratory data and provide 
assistance to the clinician in creating a more comprehensive clinical perspective for 
diagnosis and management of patients [10]. Of particular importance is the use of reference 
values as surrogate markers for monitoring disease progression and response to 
antiretroviral therapy in HIV-infected individuals [11]. For example, decisions to initiate, 
continue, or change antiretroviral therapy regimens are determined using CD4+ T-
lymphocyte cell (CD4) counts, while drug toxicity is monitored using liver function tests,  
renal function tests, and full blood counts (FBC) [12, 13]. The hemoglobin concentration is 
used as a marker of anemia. As part of the management of anemia, the clinician conducts 
additional tests to identify a reversible etiology for anemia (eg, iron deficiency, infection) 
and if present treats it appropriately. However, in the clinical environment, the statistical 
definition of reference intervals may not allow certain clinical uses. Because these reference 
intervals have been derived statistically from a healthy population, they may not be used to 
rule in or rule out specific medical conditions. The statistically derived 95% reference 
interval would mean that 5% of normal subjects would have abnormal laboratory values. 
This is erroneously interpreted that 95% of diseased individuals would fall outside the 
derived reference interval. It is recommended that the number of diseased individuals who 
fall outside the defined 95% reference intervals be determined through a study of the 
distribution of such persons with the target condition [14]. Thus, it is necessary to confirm 
the validity of the proposed reference intervals with clinicians using a particular test to 
manage patients. 
In the research environment, however, the aim is to define a reference population that is as 
similar as possible to that for which a particular test will be applied with the exception of the 
presence of the disease. During clinical trials, reference intervals relevant to the study of 
interest are required to interpret normal values of standard laboratory test results from the 
target population [15]. This is particularly important during phase I/II safety trials where 
healthy individuals are assessed without a control group [15-17]. Moreover, clinical 
reference intervals are necessary in order to accurately assess potential adverse events 
observed during the course of clinical trials. 
2.2. Consequences of misclassification 
A majority of clinically healthy participants have been excluded from several clinical trials 
in Africa because laboratory hematological and biochemical parameters are classified as 
abnormal [18-20]. Unnecessary exclusion of potential participants generally results in 
increased cost for study recruitment to achieve the target sample size. Accurate reference 
intervals are required for monitoring adverse events during vaccine and drug trials to limit 
misclassification that might otherwise lead to discontinuation of such trials or erroneous 
conclusions that the trial interventions are associated with adverse events. A study 
documented that the expense of adverse event investigation and reporting accounted for at 
least one-third of the study cost, irrespective of the adverse event grade [18].  To overcome 
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these challenges, there is a need to establish accurate, locally derived reference intervals for 
the target population. Within the last decade, several studies in sub-Saharan Africa have 
attempted to establish hematological and biochemical reference intervals for use in clinical 
monitoring and patient management. 
2.3. Selection of a reference population 
The selection of a reference population is as per described in the Clinical Laboratory 
Standards Institute (CLSI, Wayne, PA, USA) guidelines [21]. The guidelines state that 
reference individuals selected for the determination of reference intervals should closely 
resemble the patient population undergoing medical examination and should be of similar 
age to be clinically significant [21]. The reference individuals should not be hospital or clinic 
patients unless absolutely necessary. The guidelines describe two selection methods for a 
reference population: a priori and a posteriori. A priori sampling method involves selection of 
reference individuals based on well-defined exclusion and partition criteria. The entire 
selection process takes place before any blood sample is drawn and a sufficient number of 
reference individuals are targeted to provide statistical validity. A posteriori sampling 
method involves selection of the reference population after the analyte has been tested. The 
CLSI guidelines recommend a minimum of 120 individuals to allow 90% confidence limits to 
be non-parametrically calculated for the reference limits [22]. Partitioning of reference intervals 
either by gender or age is recommended if clinically useful or physiologically well grounded. 
Even though 120 samples remains the recommended standard, an efficient laboratory, by 
considering the CLSI revised guideline strategies [8], can determine reference intervals using 
fewer samples [23]. Alternatively, a laboratory can adopt reference intervals established from 
another laboratory if the values are verified using the procedures set out in the guidelines.  
In our study [9] of adolescents and adults living in rural western Kenya, all participants 
were screened by a review of medical history, a physical examination, tested for HIV and 
pregnancy (for females), and treated for any illnesses diagnosed. Participants were included 
if they were a permanent resident of the study area, between 13 and 34 years of age and able 
to provide informed consent or assent if a minor. Participants were excluded if they were 
HIV-seropositive, pregnant, exhibiting febrile symptoms or on any medication. Blood 
samples were therefore obtained from clinically healthy participants selected to generate 
hematologic and biochemical reference intervals. Data were partitioned by age (<18 years of 
age as adolescents and ≥18 as adults) and gender; median and 95th percentile intervals were 
calculated. The lower 95% reference limit was defined as the 2.5th percentile while the 
upper limit was defined as the 97.5th percentile. A Wilcoxon rank-sum test was used to test 
for age and gender differences.  We compared our data against reference intervals from the 
Massachusetts General Hospital (MGH-USA) [6] and the U.S. NIH Division of AIDS 
(DAIDS) toxicity tables [7] to determine the number of study participants with values 
outside the MGH ranges or who had any adverse event as graded by the DAIDS criteria. 
However, while the CLSI guidelines recommend a description of the population from which 
reference intervals are derived, the DAIDS and Massachusetts General Hospital reference 
values do not provide such information. 
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3. Current status of reference values in Africa 
Reference intervals for clinical laboratory parameters have traditionally been obtained from 
European and North American populations [2]. However, differences have been reported 
between these values when compared to healthy African population values  [16]. These 
include lower hemoglobin, red blood cell counts, hematocrit, mean corpuscular volume, 
platelets and neutrophils, and higher monocyte and eosinophil levels for African population 
compared to their Western counterparts [16,24-26] and Africans of European decent [27, 28]. 
Moreover, variations in several indices have been reported between different African ethnic 
groups [26, 29-31]. These differences are postulated to occur due to factors such as genetics, 
dietary patterns, gender, age, ethnic origin and environmental pathogens which are known 
to influence hematological and immunologic indices [32-35].  
While the differences observed in some laboratory parameters between African and 
Caucasian/Western populations may be attributed to nutritional differences, genetic 
polymorphisms, or more intense environmental exposure to endemic pathogens, it must be 
stressed that these reference values are being derived from population-based statistical 
analyses of norms among healthy persons.  For example, healthy Africans tend to have 
lower white blood cell counts than Caucasians, but there is no evidence that they suffer any 
additional risk of developing severe infection or other sequelae.  Also, African American 
populations, with environmental exposures more like their white American counterparts, 
tend to have lower ‘normal values’ in hematologic parameters than Caucasian Americans, 
suggesting a genetic basis for these population differences. 
3.1 Variation in specific laboratory parameters 
a. Hematologic parameters 
The normal values of red cell counts and indices (i.e., hemoglobin concentration, hematocrit,  
mean corpuscular volume, red blood cell count), white cell counts and platelet counts are 
known to vary with age, sex and pregnancy [9, 16, 20, 31, 36]. In addition, genetic and 
environmental factors can also affect the reference intervals in certain populations [32-34, 
37]. It is of particular importance that these differences in reference intervals be considered 
by clinicians in different settings. 
i. Red blood cell (RBC) components 
African RBC component values were significantly lower when compared to reference 
intervals obtained from the Massachusetts General Hospital [6] from a North American 
population, and thus a significant proportion are misclassified when the NIH DAIDS 
toxicity tables are applied [9, 34, 38]. Differences observed in the RBC components between 
African and Caucasian populations may be attributed to lower dietary iron intake, genetic 
polymorphisms such as thalassemia and sickle cell trait or chronic exposure to endemic 
parasites including helminths, malaria and schistosomiasis.   
Statistically significant differences in median RBC, hemoglobin concentration (Hb) and 
hematocrit (Hct), mean corpuscular volume (MCV) and mean corpuscular hemoglobin 
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(MCH) by gender have been observed in several African studies, with adult males having 
higher values than adult females in East Africa [9, 16, 20, 31, 39, 40], Southern Africa [20, 36], 
West Africa [41] and Central Africa [42]. These gender differences in RBC parameters as 
illustrated in our findings (Table 2), are consistent with previously established evidence that 
males have higher values than females for these parameters and is partly attributed to the 
influence of the androgen hormone on erythropoiesis [43, 44] and to menstrual blood loss in 
women [16, 25, 39, 42, 45]. It has been reported that estrogens lower the Hb through 
hemodilution while testosterone increases the plasma volume but increases circulating RBC 
to an even greater extent [46]. 
 
  Age 13-17 years Age 18-34 years 
Parameter Gender  n 
Median (95th
percentile) 
p-value 
(gender)
n 
Median (95th
percentile) 
p-value 
(gender) 
p-value  
(age) 
Hemoglobin 
(g/dL) 
Female 57 12.2 (8.1 - 14.2)  <.0001 83 12.1(8.0 – 14.2) <.0001 0.3243 
Male 76 13.1 (10.6 - 15.6)  77 14.2 (11.4 - 16.9)  <.0001 
Hematocrit 
(%) 
Female 57 35.6 (24.8 - 43.1) <.0001 83 35.8 (23.2 - 44.3) <.0001 0.8015 
Male 76 38.8 (29.3 – 48.1)   77 41.7 (32.6- 51.5)  <.0001 
RBC (x1012/L) 
Female 57 4.7 (3.3 -  5.4) 0.0001 83 4.5 (3.4 - 5.7) <.0001 0.2638 
Male 76 4.9 (4.1 - 5.8)   77 5.3 (4.3 - 6.5)  <.0001 
PLT(x109/L) 
Female 57 233 (134 – 439) 0.2958 83 220 (88 – 439) 0.0222 0.4034 
Male 76 224 (103 – 386)   77 201 (102 -307)  0.0094 
WBC (x109/L) 
Female 57 5.2 (3.9-10.2) 0.6359 83 5.6 (3.3-9.7) 0.0189 0.2038 
Male 76 5.6 (3.3-8.3)  77 5.3 (2.5-7.4)  0.6382 
Lymphocytes 
(x109/L) 
Female 57 2.2 (1.1 - 3.1) 0.9820 83 2.2 (1.3 - 3.8) 0.6901 0.9388 
Male 76 2.2 (1.0 - 4.2)   77 2.2 (1.0 – 3.5)  0.585 
Ab 
Neutrophils 
(x109/L) 
Female     57 2.0 (1.0-6.2) 0.4991 83 2.3 (1.3-5.4) 0.0004 0.0576 
Male      76 1.9 (0.8-5.0)   77 2.0 (0.8-3.9)  0.6575 
CD4: 
Absolute 
Female 58 934 (465- 1553) 0.4074 83 866 (440-1602) 0.0141 0.509 
Male 76 874 (367-1571)   77 811 (462-1306)  0.0209 
CD8: 
Absolute 
Female 58 506 (195-1068) 0.4506 83 472 (262 - 1167) 0.8706 0.9213 
Male 76 468 (195-988)   77 468 (201-1104)  0.4194 
CD4/CD8 
ratio 
Female 58 1.8 (0.9-3.2) 0.9215 83  1.8 (0.8-3.0) 0.0728 0.4879 
Male 76 1.8 (0.8-2.8)   77 1.6 (0.8-2.8)   0.0543 
Table 2. Test of difference in hematologic and immunologic parameters between gender and age-
groups from healthy 13-34 year olds in a rural western Kenya cohort (2003-2005). 
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Age-related differences in the RBC component have also been observed among male 
participants, with adults (≥18 years) having higher levels of Hb, Hct and RBC compared to 
male adolescents (13-17 years) as shown here (Table 2) [9]. This age variation is similar to that 
reported in a study of Caucasian adolescents [34]. This difference could be attributed to higher 
levels of androgen hormones among older males. This explanation is further strengthened by 
the absence of age-related hematological difference among female participants. It has also been 
postulated that an increase in the size and mass of muscle fibers as occurs in males is 
associated with an increase in the number of circulating red blood cells [47].  
There are limited data comparing reference intervals for hematologic values among African 
children compared to Caucasian children and also few studies on relevant local reference 
values for African infants. However, these studies, similar to the adult studies, have 
highlighted differences in RBC components compared to values obtained from Caucasian 
children [48]. The lower RBC parameters, as in the adolescent and adult groups, may be 
attributed to impaired hematopoiesis as a result of lower dietary iron intake, chronic blood 
loss due to hookworm infestation or chronic malaria infection [25]. Endemic sickle cell trait 
(HbS) and α-thalassemia may also play an important role [49]. 
ii. Platelets 
In general, lower platelet counts are more common in African than in Western populations. 
While the lower platelet counts in African populations are consistent in several African 
studies [24, 25, 30, 31, 40], its etiology is unknown. Possibilities such as dietary, 
environmental and genetic factors have been proposed [24, 30, 31]. Nevertheless, the 
significant difference in the lower limit of the reference interval between African and 
Caucasian populations warrants consideration when interpreting platelet counts in patients 
or during clinical trial recruitment in African populations. 
Among Africans males, significant age-related differences have been observed in platelet 
counts with adults having higher platelet counts compared to adolescents [9]. This variation 
is observed as a progressive increase with age from adolescence to young adulthood. In 
comparison, there is little age variation in platelet counts among females. However, females 
have higher platelet counts than males both in adolescence [9] and adulthood [9, 16]. These 
gender differences in platelet counts have been attributed to hormonal influences [50]. 
Platelet count have been observed to falls at the onset of menstruation while peak values are 
obtained in mid-cycle indicating that hormonal influences and/or menstrual blood loss may 
be involved [27]. While platelet levels remain stable during pregnancy, a decrease has been 
reported immediately after delivery, likely due to consumption during separation and 
delivery of the placenta. 
iii. White Blood Cell (WBC) components 
A high proportion of participants in the African studies have WBC counts below the lower 
range of the Massachusetts General Hospital US population-derived values [9, 20]. This 
phenomenon is consistent with a number of studies that have reported lower WBC counts in 
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African populations and those of African ancestry, including African Americans, than in 
Caucasian populations [24, 30, 51-53]. Because the reference interval for WBC counts is 
significantly different from that of Caucasian populations, it is advisable to use appropriate 
ethnic group intervals when interpreting blood counts [31]. 
Gender differences in the WBC counts exist in both African and Caucasian populations with 
females having higher values than males [9, 20, 54]. Age-related difference in WBC counts 
has been reported in several African studies [9, 25, 33]. Adolescents have higher WBC 
counts compared to adults as shown in our study (Table 2) [9].  
1. Neutrophils 
Within the U.S., lower neutrophil counts are more common among blacks compared to 
Caucasians [28]. Thus, it is not unsurprising to observe a higher proportion of African study 
participants (22.5-35%) having neutrophil counts below the lower range of Massachusetts 
General Hospital’s population-derived reference interval [9]. It is estimated that about 25% 
to 50% of Africans have “benign ethnic neutropenia,” maintaining consistently low absolute 
neutrophil counts with no evidence of increased susceptibility to infection or other adverse 
events [28]. Possibile explanations for the lower neutrophil count include diet, genetic or 
environmental influences [53, 55].  
In general, there are significant differences in neutrophil counts between male and female 
adults, with the females having higher neutrophil counts than males. This increase in 
neutrophil counts observed in women may be related to estrogen since a decrease in counts 
has been reported after menopause [39]. Oral contraceptives have also been implicated in 
neutrophilia [56].  
Additionally, several studies in southern Africa have documented high rates of neutropenia 
in infants of women receiving Prevention of Mother to Child Transmission interventions 
[57-591]. Evaluation of neutropenia in infants receiving antiretroviral prophylaxis or 
treatment (directly or indirectly through maternal exposure in utero or through 
breastfeeding) remains a challenge. Neutropenia is a known side effect of zidovudine [60] 
and trimethoprim/sulfamethoxazole, which is often prescribed for prevention of 
opportunistic infections in HIV-infected and/or HIV-exposed infants/children. This 
problem is further compounded by the paucity of normative data for hematologic values 
in African infants.  
2. Basophils and eosinophils 
Basophil and eosinophil counts in African populations are significantly elevated in both 
genders when compared to the US-based reference intervals [9, 20]. This may be due to a 
high prevalence of parasitic infections in the environment including schistosomiasis, 
helminthic infections, perennial malaria and exposure to a broader range of environmental 
antigens [25, 39]. However, the eosinophil counts do not vary significantly by gender or by 
age, as assessed between adolescent and adult  African participants [9, 34]. 
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3. Monocytes 
Generally, no ethnic or age differences are observed between Caucasian and African 
populations [46]. Monocyte counts in Eastern and Southern Africa are comparable to the US 
derived valuesand thus there is no need for separate reference intervals [9, 20]. 
In the African studies, no differences are observed in absolute monocyte counts between 
adolescents and adults or by gender [9, 20]. Previous studies from Eastern and Southern 
African populations indicate an increase in monocyte counts in males compared with 
females but the difference is not significant [3, 24, 26, 29, 30].  
4. Lymphocytes 
Among healthy, HIV-uninfected persons, there are no significant differences in lymphocyte 
counts between Caucasian and African populations but females generally have higher 
lymphocyte counts than males [54]. This is corroborated by studies within Africa that 
indicated higher CD4 cell percentage and absolute CD4 counts in females compared to 
males [9, 26, 61].  
However, geographical variation exists in lymphocyte counts with some populations in 
Southern African showing significantly lower reference values than other parts of Africa 
[62]. In assessing age-related variability, younger age is associated with higher CD4 cell 
counts and a higher CD4:CD8 ratio. However, the differences are not significantly except for 
CD4 cell counts between male adolescent and male adults [9]. These age and geographical 
variations need to be considered when interpreting lymphocyte counts. 
b. Clinical chemistry parameters 
Most African studies [9, 15, 16, 20] report reference intervals for most parameters (creatinine, 
direct bilirubin, amylase and albumin) that are in agreement with reference intervals 
published in the United States [6]. However, certain parameters such as Creatine Kinase 
(CK) and Lactose Dehydrogenase (LDH) have upper intervals that are substantially higher 
than those published in the Massachusetts General Hospital intervals [16, 20]. Other 
parameters with a similar trend include total bilirubin (T-bil) and blood urea nitrogen 
(BUN). The upper range for T-bil is about twice as high as that of the US-derived upper 
reference limit while the lower range for BUN is a about a third of the US-derived lower 
reference limit [9, 15, 20]. The etiology of high T-bil in the African population may arise 
from a number of factors including RBC hemolysis caused by malaria infection or sickle cell 
disease, malnutrition or physical exertion. Moreover, the presence of similar trends among 
other African populations is suggestive of a common environmental or genetic factor.   
Our findings indicated gender and age variations in blood chemistry analytes of liver and 
renal function among African adolescents and adults. Male adolescents and adults had 
higher values for alanine aminotransferase (ALT), aspartate aminotransferase (AST), T-bil 
and creatinine than females adolescents and adults (Table 3). These gender differences were 
significantly greater for T-bil and creatinine in both adolescents and adults while for AST, 
the difference was significant only among the adolescents. However, these differences were 
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not clinically significant. There were no gender differences in BUN and glucose levels for all 
age groups and no significant differences in T-bil, AST, ALT and glucose between the two 
age groups for both males and females.  However adult men and women had higher values 
for creatinine and BUN compared to adolescent males and females, respectively.  
 
   Age 13-17 years   Age 18-34 years   
Parameter Gender n 
Median (95th
percentile) 
 n 
Median (95th
percentile) 
p-value 
(gender) 
p-value  
(age) 
AST/SGOT 
(μ/L) 
Female 62 22.6 (12.0 – 43.1) 0.0102 82 22.2 (13.5 - 48.5) 0.0822 0.5905 
Male 77 26.9 (17.0 – 59.2)   77 26.7 (12.5-69.3)  0.9147 
ALT/SGPT 
(μ/L) 
Female 62 17.4 (4.2-65.3) 0.6289 82 18.9 (10.7-61.3) 0.2247 0.1305 
Male 77 20.5 (4.9-42.4)   77 22.4 (12.0-80.6)  0.0901 
Total 
Bilirubin 
(μmol/L) 
Female 62 9.7 (3.7-38.5) 0.0331 82 11.5 (5.8-36.1) 0.0368 0.7132 
Male 77 13.9 (5.7 – 62.6)   77 13.8 (5.3 - 50.7)  0.6662 
Creatinine 
(μmol/L) 
Female 62 64.5 (48.0-87.6) 0.0229 82 70.7 (52.4-96.8) <.0001 0.0013 
Male 77 66.3 (49.6-103.7)   77 83.1(54.2-137.8)  <.0001 
Table 3. Test of difference in clinical chemistry parameters between gender and age-groups from 
healthy 13-34 year olds in a rural western Kenya cohort (2003-2005). 
4. Should establishing separate normal ranges for African adolescents 
and pregnant women be considered? 
A number of studies similar to our published data [9], have reported age-related variation 
between male adolescents as compared to adults for Hb, Hct and RBC levels [25, 34, 45]. 
This observation is physiologically grounded on hormonal influence and as per the CLSI 
guidelines, partitioning reference intervals by age (or other subgroup considerations) may 
be appropriate. While these observations may not be of any medical significance, it should 
be taken into consideration whenever clinical trials target this population. To satisfy the 
statistical requirement for partitioning, there is need for further research on reference values 
among adolescents, as their participation in clinical trials increases.  
Other than the RBC components mentioned above, no significant age differences have been 
observed in other laboratory parameters measured among males or in any parameters 
measured among females except for creatinine and BUN. Thus, for such parameters for 
which no differences are reported, adult values can be used in clinical trials involving 
adolescents. 
With the advent of antiretroviral therapy for HIV and other interventions to improve 
maternal and child health, pregnant women and infants have become the focus of many 
health programs. However, few data exist regarding these important populations, despite 
increased clinical trials aimed at reducing mother-to-child HIV transmission. Although 
pregnancy-induced changes occur in hematological values including Hb, Hct and RBC 
count, very few laboratories provide specific reference ranges for pregnant women [63, 64]. 
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In pregnancy, blood volume increases resulting in hemodilution. While the red cell mass 
increases during pregnancy, the plasma volume increases more resulting in a relative 
anemia. This leads to a lower Hb level, Hct and RBC. Hb is known to vary with gestational 
age with the highest values within the first and last trimesters and lowest during the second 
trimester. Similarly, the Hct and RBC decreases with gestational age.  A stable higher upper 
reference limit for WBC count during pregnancy has been reported [65, 66]. WBC count is 
known to peak at delivery, thus limiting the use of this parameter as a marker for infection 
during delivery. This increase in WBC count results primarily from an increase in neutrophil 
counts and a slight increase in lymphocyte counts.  Currently, there exists no African study 
designed to establish reference intervals during pregnancy and most laboratory information 
systems report reference values based on samples obtained from non–pregnant women 
which may not be useful for clinical decisions during pregnancy. Thus, there is an increased 
risk of overlooking important physiologic alterations resulting from pathological conditions 
and of misinterpreting normal changes as pathological events [64]. It is therefore important 
to develop reference intervals for women during pregnancy and the postpartum period for 
use in patient monitoring and management.  
5. A case for African/ Region specific toxicity tables? 
Under a research-based approach, applying the US Massachusetts General Hospital derived 
reference intervals to our reference population from western Kenya during screening for a 
clinical trial (Table 4), over 58% of the volunteers would have been excluded from the trial 
despite having laboratory results consistent with the general population from which they 
were derived. This erroneous screening out of otherwise healthy volunteers would have 
important implications on study costs, work load and time, as more volunteers would be 
need to be screened in order to meet the required target [15].  
Similarly, applying the DAIDS toxicity tables to our population, some of our calculated 
reference intervals fall between the normal, and grade 1–2 toxicity grading in the DAIDS 
system (Table 4). Using the clinic based approach, 40% of our otherwise healthy study 
participants would have erroneously been considered to have at least one laboratory-based 
grade 1–4 toxicity adverse event. The lower range for Hb, neutrophil counts, as well as the 
upper range for eosinophil counts and bilirubin would be considered as grade 2 adverse 
events, for example.  Even though studies have documented these findings, this information 
is not widely known and as a result, DAIDS has issued only 1 set of “standard” toxicity 
tables without considering racial or ethnic differences [57]. Thus, during international 
clinical trials, these tables are used as guidelines in the conduct of such trials. This may 
result in a situation where the results of a clinical trial cannot be generalized to the 
population in question since a majority of otherwise healthy participants are screened out. 
Moreover, given that the investigational product is intended for use within the same 
population being sampled, this may complicate post-market analysis or application of the 
product for the general population. Unfortunately, there are no comparable tables from 
Africa on which such clinical decisions can be based. It is therefore important that African 
countries carry out large studies in different regions of Africa for such parameters to 
establish African toxicity tables. 
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MGH USA  reference 
intervals 
(25th percentile)[6] 
Division of AIDS (DAIDS) toxicity grading 
  
out of range 
Comparison 
Grade 1 Grade 2 Grade 3 Grade 4 
Parameter n 
95th
percentile
n % n % n % n % n %  
Hemoglobin  Males (g/dl) 140 13.5-17.5 65 46 2 1.3 0 0 2 1.3 0 0 
Hemoglobin  Females 
(g/dl) 
153 12-16 61 40 11 7.9 8 5.7 14 10 0 0 
Hct (females) (%) 140 36-46 74 53         
Hct (males) (%) 153 41-53 88 58         
RBC (males) (1012 cells/L) 140 4.5-5.9 29 19         
RBC (females) (1012 cells/L) 153 4.0-5.2 32 23         
MCV (fL) 293 80-100 157 54         
Platelets (109 cells/L) 293 150-350 53 18 6 2 6 2 0 0 0 0 
WBC (109 cells/L) 293 4.5-11.0 66 23 2 0.7 0 0 0 0 0 0 
Lymphocyte count 
(109 cells/L) 
293 1.0-4.8 6 2 0 0 0 0 0 0 0 0 
Neutrophil count 
(109 cells/L) 
293 1.8-7.7 110 38 25 8.5 9 3.1 1 0.3 0 0 
Eosinophil (109 cells/L) 293 0-0.5 130 44 60 20.5 12 4.1 0 0 0 0 
Basophil count (109 cells/L) 293 0-0.2 5 2         
Monocyte count  
(109 cells/L) 
293 0-0.8 0 0         
ALT (SGPT) (U/ L) 293 0-35 30 10 12 4.1 1 0.3 0 0 0 0 
AST (SGOT) (U/ L) 293 0-35 40 13 9 3.1 3 1 0 0 0 0 
Total Bilirubin (μmol/L) 293 5.1-17.0 90 30 37 12.7 27 9.2 4 1.4 1 0.3 
Creatinine (μmol/L) 293 0-133 4 1 4 1.4 0 0 0 0 0 0 
Glucose mmol/L 293 4.2-6.4 210 71         
BUN (mmol/L) 293 3.6-7.1 246 84         
*CD4 (Cells/ μl) 293 404-1612 6 2 3 1 1 0.3 0 0 0 0 
*CD8 (Cells/ μl) 293 220-1129 13 4         
*Reference ranges provided by Becton-Dickinson with the MultiTEST IMK Kit Reagent package (12/2000;23-3602-02) -
DAIDS- Division of AIDS tables for grading the severity of adult and pediatric adverse events [26] - MGH-
Massachusetts General Hospital weekly case records [25] 
Table 4. Frequency of adverse events and out of range values comparing western Kenyan cohort to 
DAIDS and North American derived MGH values 
6. Conclusion 
While it is desirable to generate reference intervals for different populations, the procedure 
remains a challenge due to the prohibitive cost involved in performing these studies and the 
limitation in identifying suitable healthy reference individuals. Thus, the CLSI 
recommendation that all diagnostic laboratories should determine and maintain their own 
reference interval for each laboratory parameter is impractical. The revised CLSI guidelines 
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have recommended that if it is not possible to establish detailed reference studies, then 
validation of published reference intervals can be performed using methodology tailored for 
the population served by the laboratory. As few as 20 specimens can be used to validate 
reference values within each laboratory by performing a formal outlier test. 
Given the number of clinical trials and persons receiving clinical services is expected to 
increase substantially in sub-Saharan Africa, there is a need for the establishment of locally 
derived clinical laboratory reference values to ensure appropriate general health assessment, 
treatment monitoring, and efficient implementation of clinical trials. Even more important is 
the need for the establishment of toxicity grading tables for application in clinical care 
among Africans based on the documented differences between laboratory reference values 
from African populations and Caucasians or Western populations of mixed ethnic origin.  
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